---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-256458"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2026-06-04T11:16:36+00:00"
generated_at: "2026-06-04T11:20:08.159075+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Syndax raises $250M via 2.25% convertible notes due 2031; conversion price at 35% premium

## Summary
- $250M aggregate principal, 2.25% interest, semiannual payments starting Dec 15, 2026, maturing June 15, 2031.
- Net proceeds ~$243M after fees; used for general corporate purposes including R&D, commercialization, and BD.
- Initial conversion rate 40.3894 shares per $1,000 principal, equivalent to ~$24.76/share (35% premium over June 3 closing).
- Notes are senior unsecured; callable only after June 20, 2029 if stock price exceeds 130% of conversion price.
- Conversion permitted upon certain stock price thresholds or specified corporate events; company may settle in cash, stock, or mix.

## SEC filing metadata
- accession: 0001193125-26-256458
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2026-06-04T11:16:36+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000119312526256458/0001193125-26-256458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000119312526256458/d65010d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-256458
- JSON: https://secwatch.observer/filing/0001193125-26-256458.json
- Plain text: https://secwatch.observer/filing/0001193125-26-256458.txt

## Key facts
- Equity Issuances
  Syndax Pharmaceuticals Inc issued convertible note to certain investors for $250.0 million aggregate principal amount.
  - Security: convertible note
  - Purchaser: certain investors
  - Consideration: $250.0 million aggregate principal amount
  source text: the Company will issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000119312526256458/0001193125-26-256458-index.htm
- Material Agreements
  Syndax Pharmaceuticals Inc entered into Indenture with U.S. Bank Trust Company, National Association valued at $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (effective 2026-06-03).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: U.S. Bank Trust Company, National Association
  - Value: $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031
  - Effective: 2026-06-03
  source text: On June 3, 2026, Syndax Pharmaceuticals, Inc. (the “ Company ”) entered into privately negotiated subscription agreements (the “ Subscription Agreements ”) with certain investors, pursuant to which the Company will issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the “ Notes ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000119312526256458/0001193125-26-256458-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.